# PSMD14

Source: https://onco.cc/targets/psmd14/  
OnCo record `psmd14` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

PSMD14 (Ubiquitin C-terminal hydrolase PSMD14) is an enzyme. The public catalogues list it as a drug target and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.

## Summary

Component of the 26S proteasome, a multiprotein complex involved in the ATP-dependent degradation of ubiquitinated proteins. This complex plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins, which could impair cellular functions, and by removing proteins whose functions are no longer required. Therefore, the proteasome participates in numerous cellular processes, including cell cycle progression, apoptosis, or DNA damage repair.

Open Targets scores its association with cancer at 0.64 (direct and indirect evidence; datatypes literature 0.98, genetic association 0.03, clinical 0.99).

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: proteasome 26S subunit, non-ATPase 14; Ubiquitin C-terminal hydrolase PSMD14; POH1; pad1; Rpn11
- Tags: cancer-genes-wave
- Symbol: PSMD14
- Class: enzyme
- Biology: Component of the 26S proteasome, a multiprotein complex involved in the ATP-dependent degradation of ubiquitinated proteins. This complex plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins, which could impair cellular functions, and by removing proteins whose functions are no longer required. Therefore, the proteasome participates in numerous cellular processes, including cell cycle progression, apoptosis, or DNA damage repair. The PSMD14 subunit is a metalloprotease that specifically cleaves 'Lys-63'-linked polyubiquitin chains within the complex. Plays a role in response to double-strand breaks (DSBs): acts as a regulator of non-homologous end joining (NHEJ) by cleaving 'Lys-63'-linked polyubiquitin, thereby promoting retention of JMJD2A/KDM4A on chromatin and restricting TP53BP1 accumulation. Also involved in homologous recombination repair by promoting RAD51 loading. Locus 2q24.2 (HGNC).
- Where found: Multiple myeloma: Open Targets association 0.61 with plasma cell myeloma (MONDO_0009693); Non-Hodgkin lymphoma: Open Targets association 0.57 with non-Hodgkin lymphoma (MONDO_0018908); Mantle cell lymphoma: Open Targets association 0.54 with mantle cell lymphoma (MONDO_0018876)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.99; UniProt keyword "DNA repair". Evidence tier "approved-drug" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:16889: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16889
- UniProt O00487: https://www.uniprot.org/uniprotkb/O00487/entry
- NCBI Gene 10213: https://www.ncbi.nlm.nih.gov/gene/10213
- Ensembl ENSG00000115233: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000115233

## Connected records

- collections: [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/), [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)

---
JSON: https://onco.cc/api/v1/entities/psmd14.json